EC authorises Sydnexis’ paediatric myopia treatment

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

Jun 7, 2025 - 06:00

EC authorises Sydnexis’ paediatric myopia treatment

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

Read the original article

Tags:

Previous Article

Juvenescence enhances AI drug discovery with Ro5 acquisition

‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

How did hiring in the Asia-Pacific pharma industry perform in Q2 2023

How did hiring in the Asia-Pacific pharma industry perf...

Jul 29, 2023

Alvotech and Dr Reddy’s partner to commercialise AVT03

Alvotech and Dr Reddy’s partner to commercialise AVT03

May 23, 2024

CervoMed’s stock rises as FDA grants orphan drug status to dementia drug

CervoMed’s stock rises as FDA grants orphan drug status...

Nov 29, 2024